The potential promise of BLZ-100 or “tumor paint”

There has been a lot of media interest in the past couple of weeks in a new technology that may be very helpful in enhancing the visibility of cancerous tissues and the ability to differentiate visually between cancerous and healthy tissue. … READ MORE …

Canadian scientists to get major grant from Movember Foundation

According to media reports, the Movember Foundation has just awarded $4.7 million to “a team of Canadian scientists” to support the development of molecular diagnostic tests that could be used to guide the treatment of prostate cancer. … READ MORE …

Quality of life after standard therapies for localized prostate cancer

Assessment of patient quality of life (QoL) after standard forms of treatment for localized prostate cancer is difficult for many reasons — not least because there is no real agreement among members of the research community about the best ways to measure QoL or patient satisfaction after treatment. … READ MORE …

IGF1 and risk for prostate cancer among African Americans

There have been suggestions that genetic variations in subtypes of insulin-like growth factor 1 (IGF1) might be responsible for at least some of the increase in risk for prostate cancer among African Americans and others of historic African ethnicity such as Afro-Caribbeans. … READ MORE …

Is baseline free serum T a factor in appropriate management on active surveillance?

Analysis of data from a cohort of 154 Chilean men with prostate cancer, all being monitored on active surveillance, suggests that free serum testosterone levels (but not total testosterone levels) may be able to help to predict which of these men will go on to need active treatment. … READ MORE …

ART or SRT in high-risk patients post-surgery?

As many of our regular readers will know, there is no clear answer to the question whether, among men at elevated risk of progressive disease after first-line surgery, it is better to have adjuvant radiation therapy (ART) within a few months of surgery or to wait until salvage radiation therapy (SRT) is clearly advisable. … READ MORE …

The absolute increase in risk of prostate cancer after a vasectomy

Late last week we commented briefly on a paper by Siddiqui et al. that had assessed the association between risk for a diagnosis of prostate cancer and the prior occurrence of a vasectomy in men who participated in the Health Professionals Follow-up Study (HPFS). … READ MORE …

5-ARIs and risk for high-grade prostate cancer: yet another data set

The question of whether the use of 5α-reductase inhibitors (5-ARIs) like finasteride (Proscar) and dutasteride (Avodart) is really associated with a significantly increased risk for diagnosis of high-risk and/or lethal prostate cancers remains unanswered. However, yet another set of data from the Health Professionals Follow-up Study (HPFS) has offered us some additional insights. … READ MORE …

Sociodemographics and 10-year prostate cancer survival data

The issue of sociodemographic inequality in the delivery of cancer care is well understood in America — and we don’t really know how to provide a high quality of care to those who are disadvantaged by economic factors, racial factors, or other demographic factors (such a rural vs. urban issues of access to care). … READ MORE …

If you’re already depressed, you may need help to make good decisions

In a rather less that surprising finding, a new paper in the Journal of Clinical Oncology reports that men with existing depressive disorders at the time of diagnosis with prostate cancer “are less likely to undergo definitive treatment and experience worse overall survival.” … READ MORE …

Vasectomy and prostate cancer — the debate evolves

As regular readers will be well aware, the question of whether there is a real cause and effect association between having a vasectomy and the later risk for diagnosis of prostate cancer is controversial and unanswered in any absolute sense. However, there are new data that we can now put on the table … … READ MORE …

USPSTF on PSA screening … a current update …

The U.S. Preventive Services Task Force (USPSTF) has just issued its “Guide to Clinical Preventive Services” for 2014. The publication (which is available on line) includes summary information about screening for prostate cancer. … READ MORE …

Maybe this time … a real answer to the value of PSA screening?

We have frequently referred to an ongoing trial in the UK known as the ProtecT trial. That trial is comparing the effectiveness and safety of surgery, radiation therapy, active surveillance as treatments for well-characterized men diagnosed with localized prostate cancer … but there is something else important we hadn’t realized … … READ MORE …

How many miles do you cycle each week?

A recently reported study from the UK — an element of the Cycling for Health UK Study — has suggested the possibility of an association between regular cycling, the intensity of cycling (in hours per week), and risk for a diagnosis of prostate cancer. However, this study does need to be read with great care. … READ MORE …

Risk for 120-day prostate biopsy-specific mortality — redux

Once upon a time (not so very long ago) Boniol et al. suggested that the 120-day mortality rate associated with biopsies for risk of prostate cancer might be as high as 1.3 percent. This caused something of a furore. … READ MORE …

Follow

Get every new post delivered to your Inbox.

Join 1,117 other followers